Advanced

Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumours

Vidarsdottir, Halla LU ; Siesing, Christina LU ; Nodin, Björn LU ; Jönsson, Per ; Eberhard, Jakob LU ; Jirström, Karin LU and Brunnström, Hans LU (2021) In Journal of Surgical Oncology 123(4). p.1144-1156
Abstract
Background
The lungs are the second most common site of metastases in colorectal cancer (CRC). The aim of this study was to investigate prognostic factors, including RNA‐binding motif protein 3 (RBM3) expression, in patients with CRC treated with pulmonary metastasectomy (PM).

Methods
The cohort included all patients treated with PM at Skåne University Hospital, Lund, Sweden, from 2000 to 2014. Clinicopathological, treatment, and survival data were collected. Immunohistochemical staining of RBM3 was evaluated on tissue microarrays with samples from all lung metastases and a subset of paired primary tumors. Kaplan–Meier analysis and Cox proportional hazards modeling were applied to examine the associations of investigative... (More)
Background
The lungs are the second most common site of metastases in colorectal cancer (CRC). The aim of this study was to investigate prognostic factors, including RNA‐binding motif protein 3 (RBM3) expression, in patients with CRC treated with pulmonary metastasectomy (PM).

Methods
The cohort included all patients treated with PM at Skåne University Hospital, Lund, Sweden, from 2000 to 2014. Clinicopathological, treatment, and survival data were collected. Immunohistochemical staining of RBM3 was evaluated on tissue microarrays with samples from all lung metastases and a subset of paired primary tumors. Kaplan–Meier analysis and Cox proportional hazards modeling were applied to examine the associations of investigative factors with overall survival (OS) and recurrence‐free survival.

Results
In total, 216 patients with a primary tumor in the rectum (57%), left colon (34%), or right colon (9%) underwent PM. The 5‐year OS rate was 56%. Age > 60 years, more than one metastasis, size of metastasis > 3 cm, disease‐free interval < 24 months, low RBM3 score in the lung metastasis, and no adjuvant chemotherapy following PM were prognostic factors for shorter OS.

Conclusions
Several prognostic factors, including RBM3 expression, may be of aid in selecting CRC patients with lung metastases for PM as well as adjuvant therapy. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Surgical Oncology
volume
123
issue
4
pages
1144 - 1156
publisher
Wiley-Blackwell
ISSN
0022-4790
DOI
10.1002/jso.26375
language
English
LU publication?
yes
id
a3d1b064-b825-43a2-b480-928d1ea1e5d9
date added to LUP
2021-05-09 15:51:06
date last changed
2021-05-10 10:31:05
@article{a3d1b064-b825-43a2-b480-928d1ea1e5d9,
  abstract     = {Background<br>
The lungs are the second most common site of metastases in colorectal cancer (CRC). The aim of this study was to investigate prognostic factors, including RNA‐binding motif protein 3 (RBM3) expression, in patients with CRC treated with pulmonary metastasectomy (PM).<br>
<br>
Methods<br>
The cohort included all patients treated with PM at Skåne University Hospital, Lund, Sweden, from 2000 to 2014. Clinicopathological, treatment, and survival data were collected. Immunohistochemical staining of RBM3 was evaluated on tissue microarrays with samples from all lung metastases and a subset of paired primary tumors. Kaplan–Meier analysis and Cox proportional hazards modeling were applied to examine the associations of investigative factors with overall survival (OS) and recurrence‐free survival.<br>
<br>
Results<br>
In total, 216 patients with a primary tumor in the rectum (57%), left colon (34%), or right colon (9%) underwent PM. The 5‐year OS rate was 56%. Age &gt; 60 years, more than one metastasis, size of metastasis &gt; 3 cm, disease‐free interval &lt; 24 months, low RBM3 score in the lung metastasis, and no adjuvant chemotherapy following PM were prognostic factors for shorter OS.<br>
<br>
Conclusions<br>
Several prognostic factors, including RBM3 expression, may be of aid in selecting CRC patients with lung metastases for PM as well as adjuvant therapy.},
  author       = {Vidarsdottir, Halla and Siesing, Christina and Nodin, Björn and Jönsson, Per and Eberhard, Jakob and Jirström, Karin and Brunnström, Hans},
  issn         = {0022-4790},
  language     = {eng},
  month        = {03},
  number       = {4},
  pages        = {1144--1156},
  publisher    = {Wiley-Blackwell},
  series       = {Journal of Surgical Oncology},
  title        = {Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumours},
  url          = {http://dx.doi.org/10.1002/jso.26375},
  doi          = {10.1002/jso.26375},
  volume       = {123},
  year         = {2021},
}